Crewe Advisors LLC Has $115,000 Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Crewe Advisors LLC reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 13.2% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 1,670 shares of the biopharmaceutical company’s stock after selling 254 shares during the quarter. Crewe Advisors LLC’s holdings in Gilead Sciences were worth $115,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the company. Institute for Wealth Management LLC. raised its holdings in shares of Gilead Sciences by 1.9% in the second quarter. Institute for Wealth Management LLC. now owns 7,551 shares of the biopharmaceutical company’s stock valued at $518,000 after purchasing an additional 142 shares during the last quarter. First Affirmative Financial Network boosted its stake in shares of Gilead Sciences by 3.5% in the 1st quarter. First Affirmative Financial Network now owns 4,342 shares of the biopharmaceutical company’s stock worth $318,000 after buying an additional 147 shares during the last quarter. Rathbones Group PLC grew its holdings in shares of Gilead Sciences by 3.7% in the fourth quarter. Rathbones Group PLC now owns 4,185 shares of the biopharmaceutical company’s stock valued at $339,000 after acquiring an additional 150 shares in the last quarter. MCF Advisors LLC increased its position in shares of Gilead Sciences by 2.1% during the first quarter. MCF Advisors LLC now owns 7,348 shares of the biopharmaceutical company’s stock valued at $538,000 after acquiring an additional 152 shares during the last quarter. Finally, Westside Investment Management Inc. lifted its holdings in Gilead Sciences by 0.6% during the second quarter. Westside Investment Management Inc. now owns 26,526 shares of the biopharmaceutical company’s stock worth $1,826,000 after acquiring an additional 152 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Price Performance

Gilead Sciences stock traded down $0.45 during midday trading on Friday, reaching $79.00. 6,204,884 shares of the stock were exchanged, compared to its average volume of 7,175,005. The company’s fifty day moving average is $72.93 and its 200-day moving average is $70.32. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.94 and a current ratio of 1.08. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $87.86. The firm has a market cap of $98.42 billion, a PE ratio of 219.44, a PEG ratio of 3.37 and a beta of 0.18.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 27th. Shareholders of record on Friday, September 13th will be paid a $0.77 dividend. The ex-dividend date is Friday, September 13th. This represents a $3.08 dividend on an annualized basis and a yield of 3.90%. Gilead Sciences’s dividend payout ratio is currently 855.56%.

Insider Activity

In other news, insider Johanna Mercier sold 5,490 shares of the firm’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total transaction of $406,150.20. Following the sale, the insider now owns 114,979 shares in the company, valued at approximately $8,506,146.42. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, insider Johanna Mercier sold 5,490 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total value of $406,150.20. Following the completion of the sale, the insider now owns 114,979 shares in the company, valued at approximately $8,506,146.42. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $68.63, for a total transaction of $137,260.00. Following the completion of the sale, the insider now owns 96,380 shares of the company’s stock, valued at $6,614,559.40. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on GILD shares. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $70.00 target price on shares of Gilead Sciences in a research report on Friday, August 9th. Raymond James upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 price objective for the company in a report on Monday, July 8th. BMO Capital Markets boosted their target price on shares of Gilead Sciences from $80.00 to $85.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Evercore ISI upgraded shares of Gilead Sciences to a “strong-buy” rating in a research note on Friday, August 9th. Finally, Royal Bank of Canada upped their price objective on Gilead Sciences from $71.00 to $72.00 and gave the company a “sector perform” rating in a research note on Friday, August 9th. Twelve equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $81.94.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.